[Inhibition of neuronal death by promoting degradation of intracellular amyloid beta-protein].
[Inhibition of neuronal death by promoting degradation of intracellular amyloid beta-protein].
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
JP · Author affiliation · country only
Department School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Japan. ohyagi@neuro.med.kyushu-u.ac.jpLocation evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Inhibition of aggregation of amyloid p-protein (AP) and promotion of extracellular AM removal are known as potent therapeutic tools for Alzheimer's disease (AD). While, the importance of Af342 accumulating in neurons has recently been suggested, and we have reported that A/42 accumulating in the neurons moves into the nucleus, activating p53 mRNA expression and leading to apoptosis (Ohyagi et al, FASEB J, 2005). Moreover, intraneuronal Ap is reported to induce mitochondrial dysfunction via binding ABAD, synaptic pathology, and inhibition of proteasome. Thus, it is an alternative therapeutic tool to decrease the levels of A342 and p53 proteins in AD neurons. We established a human neuroblastoma (SH-SY5Y) cell culture system in which AV peptide is artificially accumulated in cytosol. We have found that apomorphine hydrochloride promotes degradation of intracellular AM and p53 attenuating oxidative stress-induced apoptosis. Using a proteasome activity assay method, one of the mechanisms is thought to be activation of proteasome. Similar anti-apoptotic effect was observed in the primary cultured neurons. Apomorphine hydrochloride is now used as a dopamine agonist for Parkinson's disease or an anti-ED drug in western countries, but also may be one of the candidate drugs to inhibit neuronal death in AD.